Nicotine Dependence clinical trials

Explore recruiting nicotine dependence clinical trials.

Recruiting nicotine dependence studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Nicotine Dependence trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

An open-label, randomised, single-dose, three-way cross-over trial to assess the pharmacokinetics of NIC24-01 and NIC24-02 oromucosal pouches (a nicotine replacement therapy) in comparison to Nicorette® 4 mg gum in healthy adult smokers under fasted conditions.

Sweden

Human Pharmacology (Phase I)- Other EU CTIS Study details

Cytisine in prolonged dosage versus Nicotine Replacement Therapy in nicotine-dependent patients with Chronic Kidney Disease - single-center, randomized, non-inferiority clinical trial.

Poland

Therapeutic use (Phase IV) EU CTIS Study details

Clinical trial to compare availability in the body of the active substance nicotine as well as patch adhesion of the newly developed patch LTS Nicotine TTS vs. Nicotinell® (21 mg/24 h) in healthy smokers after single patch application

Germany

Human Pharmacology (Phase I)- Bioequivalence Study EU CTIS Study details

Can a one-off administration of psilocybin reduce alcohol intake in patients with alcohol use disorder? A randomized, double-blinded, placebo-controlled clinical trial.

Denmark

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A randomized, double-blind, placebo-controlled trial of semaglutide for reducing cannabis use in adults with cannabis use disorder

Denmark

Therapeutic exploratory (Phase II) EU CTIS Study details

Does the Glucagon-like Peptide 1 (GLP-1) receptor agonist semaglutide reduce alcohol intake in patients with Alcohol Use Disorder and comorbid obesity?

Denmark

Therapeutic exploratory (Phase II) EU CTIS Study details

Nicotine Dependence trials by city

Nicotine Dependence in Toronto Nicotine Dependence in Vancouver Nicotine Dependence in Montreal Nicotine Dependence in Calgary Nicotine Dependence in Edmonton Nicotine Dependence in Ottawa Nicotine Dependence in Winnipeg Nicotine Dependence in Quebec City Nicotine Dependence in Hamilton Nicotine Dependence in Kitchener Nicotine Dependence in London Nicotine Dependence in Halifax Nicotine Dependence in New York Nicotine Dependence in Los Angeles Nicotine Dependence in Chicago Nicotine Dependence in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease